Noerr advises Quirin Privatbank on rights issue by Epigenomics AG

Noerr has advised Quirin Privatbank AG on a capital increase in the form of a rights issue with subscription rights by Epigenomics AG in return for cash and non-cash contributions, issuing 12,007,180 new registered ordinary shares.

The gross issue proceeds from the capital increase are approximately €22.33 million, of which the company receives around €21.25 million in cash. The remaining amount was provided by a shareholder as a contribution in kind consisting of its redemption claim under a convertible bond. Epigenomics intends to use the net issue proceeds from the capital increase primarily to repay the above convertible bond, to satisfy payment obligations falling due in the next twelve months and for general business purposes. In the transaction Quirin Privatbank AG acted as the bookrunner in Europe and sole underwriter.

Noerr partners Laurenz Wieneke (Frankfurt) and Stephan Schulz (Hamburg) coordinated the transaction. Noerr’s Financial Markets team advises Quirin Privatbank AG regularly on capital markets transactions.

Advisors to Quirin Privatbank AG: Noerr LLP

Dr Laurenz Wieneke (Frankfurt), Dr Stephan Schulz (Hamburg, both Financial Markets, joint lead), associate: Dr Anca David (Financial Markets, Hamburg)